$34.84
-0.20(-0.58%)
Mkt Cap $5.8B
$26.13
$35.36
52-Week Range
At a Glance
AI-generatedRevenue breakdown: Product (25.7%), Manufactured Product And Royalty (24.3%), Royalty (19.4%).
8-K
Alkermes plc completed the acquisition of Avadel Pharmaceuticals plc for $21.00 per share in cash plus a contingent value right (CVR). To finance the $1.525 billion transaction, Alkermes entered into new senior secured term loan facilities and terminated a prior bridge agreement.$5.8B
Market Cap
$1.5B
Revenue
$245M
Net Income
Employees1,800
Fundamentals
How The Business Makes Money
Revenue by Segment
Product25.7%($3.2B)
Manufactured Product And Royalty24.3%($3.0B)
Royalty19.4%($2.4B)
Vivitrol10.7%($1.3B)
Aristada And Aristada Initio8.4%($1.0B)
LYBALVI6.6%($819M)
Manufacturing Revenue5%($616M)
Research And Development0%($22.0K)
Revenue by Geography
US78.5%($4.3B)
European Union13.8%($750M)
Foreign Country Excluding Specified Country7.7%($419M)
IE0.1%($3M)
Activity
What Changed Recently
Company Profile
CIK0001520262
ISINIE00B56GVS15
CUSIPG01767105
Phone353 1 772 8000
AddressConnaught House, Dublin, 4, IE
SEC EDGAR